Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C17H19N3O4S |
Molecular Weight | 361.415 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N=C)C3=CC=CC=C3)C(O)=O
InChI
InChIKey=FZECHKJQHUVANE-MCYUEQNJSA-N
InChI=1S/C17H19N3O4S/c1-17(2)12(16(23)24)20-14(22)11(15(20)25-17)19-13(21)10(18-3)9-7-5-4-6-8-9/h4-8,10-12,15H,3H2,1-2H3,(H,19,21)(H,23,24)/t10-,11-,12+,15-/m1/s1
Metampicillin is the approved name for the penicillin resulting from
the reaction of ampicillin with formaldehyde. Metampicillin is hydrolysed in aqueous solution with the formation of ampicillin. Metampicillin has broad spectrum of activity coupled
with a marked degree of stability to bacterial penicillinase. Furthermore, metampicillin is reported to be absorbed to a greater extent than
ampicillin, resulting in superior blood levels in human subjects, and
also giving high levels of antibiotic in bile following parenteral administration. Metampicillin showed a spectrum and level of activity similar to that of ampicillin in vitro, and both compounds were inactive against penicillinase-producing strains of bacteria. The activity of metampicillin was markedly reduced by human
serum, and the compound was less active than ampicillin in the presence of human serum. Following the oral administration of metampicillin to man, metampicillin was not detected in the blood stream nor in urine, and ampicillin alone was demonstrated in these subjects. The serum concentrations of ampicillin that were produced following the oral administration of metampicillin were somewhat lower than those obtained with equivalent doses of ampicillin. Adminstration of metampicillin by the intramuscular (i.m.) route to volunteers resulted in the appearance
of both ampicillin and metampicillin in the blood, and of ampicillin alone in the urine of these subjects. When parenteraly administered, metampicillin appeared to be a particularly suitable penicillin for the treatment of biliary tract infections. Metampicillin is a cell wall biosynthesis inhibitor.
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
[Metampicillin in oral medicine]. | 1972 Nov 26 |
|
beta-Lactam allergenic determinants: fine structural recognition of a cross-reacting determinant on benzylpenicillin and cephalothin. | 2002 Nov |
|
Deacetoxycephalosporin C synthase isozymes exhibit diverse catalytic activity and substrate specificity. | 2003 Jan 28 |
|
Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. | 2005 Jan |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/4556172
Oral administration. Following the oral administration of a single
500-mg dose of metampicillin to fasting human subjects, metampicillin
was not detected and ampicillin alone was demonstrated in the blood
specimens taken 1, 2, and 3 h after dosing.
Intramuscular administration. After administration of 250 mg metampicillin by the i.m. route to 2 human subjects, both metampicillin
and ampicillin were observed in the blood of both subjects after 1/2 h and both penicillins were present in 1 subject 1 h after dosing.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15567297
Metampicillin interacted with renal peptide transporter PEPT2 with medium affinity (K(i)=0.1-5mM).
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1500
Created by
admin on Sat Dec 16 16:45:38 GMT 2023 , Edited by admin on Sat Dec 16 16:45:38 GMT 2023
|
||
|
WHO-VATC |
QJ01CA14
Created by
admin on Sat Dec 16 16:45:38 GMT 2023 , Edited by admin on Sat Dec 16 16:45:38 GMT 2023
|
||
|
WHO-ATC |
J01CA14
Created by
admin on Sat Dec 16 16:45:38 GMT 2023 , Edited by admin on Sat Dec 16 16:45:38 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1718
Created by
admin on Sat Dec 16 16:45:38 GMT 2023 , Edited by admin on Sat Dec 16 16:45:38 GMT 2023
|
PRIMARY | |||
|
G0H6U7VSTK
Created by
admin on Sat Dec 16 16:45:38 GMT 2023 , Edited by admin on Sat Dec 16 16:45:38 GMT 2023
|
PRIMARY | |||
|
m7266
Created by
admin on Sat Dec 16 16:45:38 GMT 2023 , Edited by admin on Sat Dec 16 16:45:38 GMT 2023
|
PRIMARY | Merck Index | ||
|
DTXSID5048479
Created by
admin on Sat Dec 16 16:45:38 GMT 2023 , Edited by admin on Sat Dec 16 16:45:38 GMT 2023
|
PRIMARY | |||
|
C005195
Created by
admin on Sat Dec 16 16:45:38 GMT 2023 , Edited by admin on Sat Dec 16 16:45:38 GMT 2023
|
PRIMARY | |||
|
METAMPICILLIN
Created by
admin on Sat Dec 16 16:45:38 GMT 2023 , Edited by admin on Sat Dec 16 16:45:38 GMT 2023
|
PRIMARY | |||
|
6713928
Created by
admin on Sat Dec 16 16:45:38 GMT 2023 , Edited by admin on Sat Dec 16 16:45:38 GMT 2023
|
PRIMARY | |||
|
229-365-6
Created by
admin on Sat Dec 16 16:45:38 GMT 2023 , Edited by admin on Sat Dec 16 16:45:38 GMT 2023
|
PRIMARY | |||
|
C87368
Created by
admin on Sat Dec 16 16:45:38 GMT 2023 , Edited by admin on Sat Dec 16 16:45:38 GMT 2023
|
PRIMARY | |||
|
52060
Created by
admin on Sat Dec 16 16:45:38 GMT 2023 , Edited by admin on Sat Dec 16 16:45:38 GMT 2023
|
PRIMARY | |||
|
DB13836
Created by
admin on Sat Dec 16 16:45:38 GMT 2023 , Edited by admin on Sat Dec 16 16:45:38 GMT 2023
|
PRIMARY | |||
|
758167
Created by
admin on Sat Dec 16 16:45:38 GMT 2023 , Edited by admin on Sat Dec 16 16:45:38 GMT 2023
|
PRIMARY | |||
|
100000081216
Created by
admin on Sat Dec 16 16:45:38 GMT 2023 , Edited by admin on Sat Dec 16 16:45:38 GMT 2023
|
PRIMARY | |||
|
CHEMBL1908324
Created by
admin on Sat Dec 16 16:45:38 GMT 2023 , Edited by admin on Sat Dec 16 16:45:38 GMT 2023
|
PRIMARY | |||
|
2570
Created by
admin on Sat Dec 16 16:45:38 GMT 2023 , Edited by admin on Sat Dec 16 16:45:38 GMT 2023
|
PRIMARY | |||
|
6489-97-0
Created by
admin on Sat Dec 16 16:45:38 GMT 2023 , Edited by admin on Sat Dec 16 16:45:38 GMT 2023
|
PRIMARY | |||
|
SUB08811MIG
Created by
admin on Sat Dec 16 16:45:38 GMT 2023 , Edited by admin on Sat Dec 16 16:45:38 GMT 2023
|
PRIMARY | |||
|
29629
Created by
admin on Sat Dec 16 16:45:38 GMT 2023 , Edited by admin on Sat Dec 16 16:45:38 GMT 2023
|
PRIMARY | RxNorm |
ACTIVE MOIETY